Elmar Schilling

Elmar Schilling's work experience includes:

- Currently serving as the Chief Technology Officer (CTO) at Omixon, a global molecular diagnostics company specializing in HLA genotyping. Elmar is responsible for overseeing the commercialization of disruptive technologies for clinical and research laboratories.

- Previously worked at Eurofins Genomics, where they held various roles such as Head of NGS Manual Innovation, Team Leader NGS, GxP Study Director & Project manager R&D, Project Manager, and R&D Manager.

- Prior to Eurofins Genomics, Elmar worked at Regensburg University Medical Center as a Postdoc and PhD student.

- Elmar also served as a Visiting Scientist at the University of North Carolina at Chapel Hill.

Elmar Schilling completed their education with a Diploma in Biology from the University of Regensburg, Department of Genetics, specializing in Genetics, Developmental Biology, and Organic Chemistry. Elmar pursued this degree from 1998 to 2004. Following this, they attended the Regensburg University Medical Center from 2005 to 2009, where they obtained a Dr. rer. nat. degree, though the field of study for this degree is not specified.